[HTML][HTML] Immune-mediated inflammatory diseases: common and different pathogenic and clinical features
G Monteleone, A Moscardelli, A Colella, I Marafini… - Autoimmunity …, 2023 - Elsevier
The term “immune-mediated inflammatory diseases (IMIDs)” refers to several inflammatory
pathologies of multifactorial etiology and involving either simultaneously or sequentially …
pathologies of multifactorial etiology and involving either simultaneously or sequentially …
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE …
X Baraliakos, A Deodhar, D Van Der Heijde… - Annals of the …, 2024 - ard.bmj.com
Objectives Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits
interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo …
interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo …
IL-17 inhibitors in axial spondyloarthritis. An overview
E Toussirot, R Felten - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction The therapeutic armamentarium for spondyloarthritis has expanded
considerably in recent years, and there is growing evidence to support the increasing use of …
considerably in recent years, and there is growing evidence to support the increasing use of …
Converging paths: Microneedle-based dual intervention of IL-23/IL-17 axis and granuloma formation in rheumatoid nodules
I Thirugnanasambandham, VVSR Karri, S Vishwas… - Medical …, 2024 - Elsevier
Rheumatoid nodules (RNs) are an extra-articular manifestation of rheumatoid arthritis and
are frequently observed in patients with autoimmune and inflammatory conditions. The …
are frequently observed in patients with autoimmune and inflammatory conditions. The …
EDIL3 alleviates Mannan-induced psoriatic arthritis by slowing the intracellular glycolysis process in mononuclear-derived dendritic cells
J Yu, X Wang, Y Zhou, J Hu, L Gu, H Zhou, C Yue… - Inflammation, 2024 - Springer
Psoriatic arthritis (PsA) is an immune-mediated, chronic inflammatory joint disease that
commonly occurs as a complication of psoriasis. EGF-like repeats and discoidal I-like …
commonly occurs as a complication of psoriasis. EGF-like repeats and discoidal I-like …
[HTML][HTML] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
PJ Mease, JF Merola, Y Tanaka, L Gossec… - Rheumatology and …, 2024 - Springer
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-
term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits …
term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits …
[HTML][HTML] Evaluating the inhibition of IL-17A and TNFα in a cartilage explant model cultured with Th17-derived cytokines
SS Groen, AC Bay-Jensen, CS Thudium… - Journal of translational …, 2024 - Elsevier
Abstract Introduction T-helper 17 (Th17) cells produce IL-17A playing a critical role in
activating the pathogenic chain leading to joint tissue inflammation and destruction …
activating the pathogenic chain leading to joint tissue inflammation and destruction …
Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models
Z Liu, L Song, J Yang, H Liu, Y Zhang, X Pi… - International …, 2024 - Elsevier
The treatment of autoimmune and inflammatory diseases often requires targeting multiple
pathogenic pathways. KYS202004A is a novel bispecific fusion protein designed to …
pathogenic pathways. KYS202004A is a novel bispecific fusion protein designed to …
[HTML][HTML] Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the
efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the …
efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the …
Интерлейкин 17 как центральный компонент патогенеза боли, связанной с иммуновоспалительным процессом: новая «мишень» фармакотерапии
АЕ Каратеев, ЕЮ Полищук… - Научно-практическая …, 2024 - rsp.mediar-press.net
Аннотация Современная патогенетическая терапия иммуновоспалительных
ревматических заболеваний (ИВРЗ) направлена не только на снижение активности …
ревматических заболеваний (ИВРЗ) направлена не только на снижение активности …